The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Martino Avallone

Martino Avallone

Doctoral student

Martino Avallone

GDNF-mediated rescue of the nigrostriatal system depends on the degree of degeneration

Author

  • Luis Quintino
  • Martino Avallone
  • Emil Brännstrom
  • Patrick Kavanagh
  • Marcus Lockowandt
  • Patricia Garcia Jareño
  • Ludivine S. Breger
  • Cecilia Lundberg

Summary, in English

Glial cell-line derived neurotrophic factor (GDNF) is a promising therapeutic molecule to treat Parkinson’s disease. Despite an excellent profile in experimental settings, clinical trials testing GDNF have failed. One of the theories to explain these negative outcomes is that the clinical trials were done in late-stage patients that have advanced nigrostriatal degeneration and may therefore not respond to a neurotrophic factor therapy. Based on this idea, we tested if the stage of nigrostriatal degeneration is important for GDNF-based therapies. Lentiviral vectors expressing regulated GDNF were delivered to the striatum of rats to allow GDNF expression to be turned on either while the nigrostriatal system was degenerating or after the nigrostriatal system had been fully lesioned by 6-OHDA. In the group of animals where GDNF expression was on during degeneration, neurons were rescued and there was a reversal of motor deficits. Turning GDNF expression on after the nigrostriatal system was lesioned did not rescue neurons or reverse motor deficits. In fact, these animals were indistinguishable from the control groups. Our results suggest that GDNF can reverse motor deficits and nigrostriatal pathology despite an ongoing nigrostriatal degeneration, if there is still a sufficient number of remaining neurons to respond to therapy.

Department/s

  • CNS Gene Therapy
  • MultiPark: Multidisciplinary research focused on Parkinson´s disease

Publishing year

2019

Language

English

Pages

57-64

Publication/Series

Gene Therapy

Volume

26

Issue

1-2

Document type

Journal article

Publisher

Nature Publishing Group

Topic

  • Medical Genetics

Status

Published

Research group

  • CNS Gene Therapy

ISBN/ISSN/Other

  • ISSN: 0969-7128